SCHEMBL5404239

SCHEMBL5404239

CCCc1nc(OC)c(N)cc1C(=O)NC(C)C(=O)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 9/20 0.46
TOP2B Q02880 8/20 0.46
POLB P06746 2/20 0.36
RAD52 P43351 2/20 0.36
MAPT P10636 2/20 0.34
TP53 P04637 3/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM1A O60341 1/20 0.33
MITF O75030 1/20 0.33
RECQL P46063 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HDAC3 O15379 1/20 0.33
APP P05067 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5398724 0.94 TOP2A (0.47) TOP2ATOP2BPOLBRAD52MAPT
SCHEMBL5404233 0.92 TOP2A (0.46) TOP2ATOP2BPOLBRAD52
SCHEMBL5394372 0.89 TOP2A (0.49) TOP2ATOP2BPOLBRAD52MAPT
SCHEMBL5401696 0.89 TOP2A (0.43) TOP2ATOP2BKDM1A
SCHEMBL5405660 0.87 TOP2A (0.41) TOP2ATOP2BPOLBRAD52TP53
SCHEMBL5401757 0.86 TOP2A (0.40) TOP2ATOP2BMAPTTP53KDM4E
SCHEMBL5398721 0.86 TOP2A (0.47) TOP2ATOP2BPOLBRAD52MAPT
SCHEMBL5401693 0.82 TOP2A (0.43) TOP2ATOP2B
SCHEMBL5394368 0.81 TOP2A (0.48) TOP2ATOP2BPOLBRAD52MAPT
SCHEMBL5452928 0.81 TOP2A (0.37) TOP2ATOP2BPOLBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230105-B2 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2007-06-12 US disclosed
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2005-10-06 US disclosed
EP-1487799-A4 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2005-06-01 EP disclosed
EP-1487799-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2004-12-22 EP disclosed
WO-2003074490-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof PARP9, CASP9, AMPD2 TOP2A 131/4885TOP2B 209/4885POLB 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.